scispace - formally typeset
L

Lin Yang

Researcher at Fudan University

Publications -  84
Citations -  803

Lin Yang is an academic researcher from Fudan University. The author has contributed to research in topics: Medicine & Exome sequencing. The author has an hindex of 11, co-authored 61 publications receiving 381 citations. Previous affiliations of Lin Yang include Boston Children's Hospital & Zhejiang University.

Papers
More filters
Journal ArticleDOI

Clinical and genetic spectrum of a large cohort of children with epilepsy in China.

TL;DR: The 12 most commonly implicated genes in this cohort and the genes with treatment options should be considered as part of the essential panel for early diagnosis of epilepsy onset, if large medical exome analyses or ES are not feasible as first-tier analysis.
Journal ArticleDOI

Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta analysis.

TL;DR: Significant different clinical features of cognitive development and psychiatric illness are associated with the Prader–Willi syndrome with different molecular defects.
Journal ArticleDOI

Clinical exome sequencing as the first-tier test for diagnosing developmental disorders covering both CNV and SNV: a Chinese cohort

TL;DR: With a higher diagnostic rate, more comprehensive observation of variations and lower cost compared with conventional strategies, simultaneous analysis of CNVs and SNVs based on CES showed potential as a new first-tier choice to diagnose DD.
Journal ArticleDOI

Optimized trio genome sequencing (OTGS) as a first-tier genetic test in critically ill infants: practice in China.

TL;DR: High-capacity OTGS testing in detecting SNVs and chromosomal abnormalities with fast response, higher diagnostic yield, and lower cost demonstrates the potential to be the first-tier of genetic testing used in critically ill infants in developing countries.
Journal ArticleDOI

Clinical utility of 24-h rapid trio-exome sequencing for critically ill infants.

TL;DR: The 24-h trio-exome sequencing (TES) can serve as a rapid response tool for patients with suspected monogenic disorders and can guide clinical decision-making in urgent cases.